SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

Automated Quality Gates

Comprehensive quality checks across hypotheses, debates, and analyses

Overall Status: CRITICAL

473 total flags across 13 active gates

157
Critical
316
Warnings
0
Passing
Missing Evidence: 49Low Scores (<0.3): 32Weak Debates: 20No KG Edges: 50Low Validation: 50Failed Analyses: 2Missing Synthesis: 7Orphaned Hypotheses: 50Thin Descriptions: 50No Target Gene: 50Duplicate / Near-Duplicate Hypotheses: 50High-Value Hypotheses With Weak Debate Support: 49Stale Market Pricing: 14

Missing Evidence — 49 flagged CRITICAL

Hypotheses with no citations or supporting evidence

Item Score/Detail Date
Multi-Clock Ensemble Discordance as a Parkinson's Disease Prodrome Detector — Epigenetic " 0.38 2026-04-26
Autophagy-Epigenetic Feedback Loop Creates a Compounding Biomarker Signal — Autophagy Flux 0.58 2026-04-26
Ethnic and Metabolic Epigenetic Clock Divergence Explains Disparate AD Risk — Hispanic/Lat 0.47 2026-04-26
Epigenetic Age Acceleration Moderates the Amyloid-to-Tau Conversion Cascade — A "Clock Thr 0.53 2026-04-26
TDP-43 Pathology Creates a Distinct Epigenetic Clock "Signature Divergence" Detectable in 0.48 2026-04-26
GrimAge Acceleration as a Cell-Type-Resolved CSF Biomarker Panel for Early AD Stratificati 0.35 2026-04-26
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16
[Archived Hypothesis] 0.30 2026-04-16

Showing 25 of 49

Low Scores (<0.3) — 32 flagged WARNING

Hypotheses with composite score below 0.3

Item Score/Detail Date
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17
[Archived Hypothesis] 0.05 2026-04-18
Alectinib's Putative C1q Binding Derives from Hydrophobic Aggregation Rather Than Direct P 0.10 2026-04-18
CD300f Immunoglobulin Receptor as Neuroinflammatory Brake 0.10 2026-04-18
P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption 0.10 2026-04-18
IL-33/ST2 Axis Augmentation for Synaptic Protection 0.10 2026-04-18
TYROBP Causal Network Inhibition for Microglial Repolarization 0.10 2026-04-18
TREM2 Agonism with CX3CR1 Antagonism for Microglial Homeostasis 0.10 2026-04-18
NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhibition 0.10 2026-04-18
AQP4 Water Channel Normalization as Surrogate Marker and Therapeutic Target 0.10 2026-04-18
C1q Binding Analysis Across ALK Inhibitor Chemical Series Would Resolve Specificity 0.12 2026-04-18
Alectinib Binds Mitochondrial C1q-like Proteins (C1QDC1) Rather Than Circulating C1q 0.12 2026-04-18
C1q Binding Reflects Broader Kinase Inhibitor Promiscuity Rather Than Specific Complement 0.12 2026-04-18
Human Serum Albumin-Mediated Displacement Creates False-Positive C1q Binding Signals 0.14 2026-04-18
Direct C1q Binding Enables FcγR-Independent Complement Activation on Tumor Cells 0.14 2026-04-18
C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated Transcytosi 0.14 2026-04-18

Showing 25 of 32

Weak Debates — 20 flagged WARNING

Debates with missing transcript or quality score <0.3

Item Score/Detail Date
Do connectivity motifs predict which cell types in a neurodegenerative mouse model will sh 0.00 / 4r 2026-04-26
Microglial senescence in Alzheimer and Parkinson disease progression 0.00 / 6r 2026-04-26
is the amyloid cascade hypothesis still important 0.00 / 0r 2026-04-24
Investigate mechanisms of epigenetic reprogramming in aging neurons 0.42 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons [TARGET_ARTIFACT type 0.50 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons 0.56 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methyla 0.48 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methyla 0.51 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methyla 0.52 / 0r 2026-04-21
Mechanistic validation of SEA-AD differential expression hypotheses: Complement C1QA layer 0.66 / 0r 2026-04-21
Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methyla 0.58 / 0r 2026-04-21
Mechanistic validation of SEA-AD differential expression hypotheses: Complement C1QA layer 0.64 / 0r 2026-04-21
Which ligand-receptor interactions between glial and neuronal populations are disrupted in 0.05 / 4r 2026-04-21
Which non-coding variants at AD GWAS loci have functional evidence for gene regulation in 0.00 / 4r 2026-04-21
Which transcription factors drive the gene regulatory networks that distinguish vulnerable 0.00 / 4r 2026-04-21
Does neuroplasticity decline with age? 0.50 / 6r 2026-04-11
TDP-43 phase separation therapeutics for ALS-FTD 0.34 / 6r 2026-04-11
What are novel CRISPR-based therapies for Huntington's disease? 0.50 / 7r 2026-04-11
Does neuroplasticity decline with age? 0.50 / 6r 2026-04-11
Test debate on neuroplasticity mechanisms 0.50 / 6r 2026-04-11

No KG Edges — 50 flagged WARNING

Completed analyses that generated no knowledge graph edges

Item Score/Detail Date
Microglial senescence in Alzheimer and Parkinson disease progression 2026-04-26
Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration 2026-04-26
What are the optimal oxygen pressure, duration, and frequency parameters for HBOT in AD tr 2026-04-26
What mechanisms drive the self-amplifying vicious cycle linking oxidative stress to cell d 2026-04-26
Does restoring neuronal AMPK activity reverse microglial inflammation in vivo? 2026-04-26
Can ferroptosis inhibitors prevent BBB disruption and edema formation after cardiac arrest 2026-04-26
Which specific factors in conditioned medium from healthy astrocytes rescue motor neuron d 2026-04-26
Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other AD hallma 2026-04-26
How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what determines 2026-04-26
Which specific CSF molecular components are essential for maintaining disease-relevant α-s 2026-04-26
Which specific transcription factors mediate MAPT suppression during proteostatic stress? 2026-04-26
What specific autophagy pathways are defective in radiation-induced pericyte senescence? 2026-04-26
How does parthenolide specifically modulate ADORA2A signaling to produce antidepressant ef 2026-04-26
What is the molecular mechanism by which rutin inhibits tau aggregation and oligomer forma 2026-04-26
Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in establis 2026-04-26
Does tau dendritic missorting persist independently after Aβ clearance, maintaining neurod 2026-04-25
Does pericyte senescence drive BBB breakdown or result from neurodegeneration as a seconda 2026-04-25
What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathol 2026-04-25
Does C1q function differ based on subcellular localization or binding partner identity? 2026-04-25
Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuc 2026-04-25
Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kina 2026-04-25
Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retention at the 2026-04-25
Allen Mouse Brain Aging Atlas: cross-age gene expression analysis 2026-04-23
Does Alectinib truly bind C1q directly with high affinity, or is this an experimental arti 2026-04-21
Is ferroptosis the primary driver of motor neuron death in ALS or an epiphenomenon of term 2026-04-18

Showing 25 of 50

Low Validation — 50 flagged WARNING

Hypotheses with evidence validation score below 0.4

Item Score/Detail Date
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30
[Archived Hypothesis] 0.30

Showing 25 of 50

Failed Analyses — 2 flagged CRITICAL

Analyses that failed to complete

Item Score/Detail Date
Connectotype-Vulnerability Mapping: testing whether mesoscale connectivity motifs predict 0 hypotheses extracted from debate 2026-04-25
Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kina Orchestrator error: name 'get_db_write' is not def 2026-04-23

Missing Synthesis — 7 flagged CRITICAL

Debates with rounds but no synthesizer step

Item Score/Detail Date
is the amyloid cascade hypothesis still important 0.00 / 0r 2026-04-24
Is the amyloid hypothesis still tractable for AD? 0.50 / 0r 2026-04-24
Neuroinflammation and microglial priming in early AD 0.95 / 3r 2026-04-04
Neuroinflammation and microglial priming in early Alzheimer's Disease 0.95 / 2r 2026-04-04
Tau propagation mechanisms and therapeutic interception points 0.95 / 3r 2026-04-04
Senescent cell clearance as neurodegeneration therapy 0.95 / 3r 2026-04-04
Cell-type specific expression patterns of neurodegeneration genes in SEA-AD 0.68 / 3r 2026-04-02

Orphaned Hypotheses — 50 flagged WARNING

Hypotheses not linked to any analysis

Item Score/Detail Date
A lower-dose 50-100 mg/day glial anti-inflammatory effect may occur, but is unlikely by it 0.48 2026-04-26
A lower trazodone dose of 50-100 mg nightly may be sufficient only in dementia patients wi 0.58 2026-04-26
High baseline tau and ISR activation may lower the effective trazodone threshold, making b 0.51 2026-04-26
Exposure profile may matter more than nominal daily dose, but formulation optimization is 0.39 2026-04-26
Direct ISR target engagement likely requires trazodone doses around 150-200 mg/day for dis 0.59 2026-04-26
Patients with OSA or high nocturnal arousal burden may require higher trazodone doses, but 0.37 2026-04-26
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Pathology Resolution (Mechanistic P 0.59 2026-04-25
Neurogranulin Predicts p-tau217 Reliability by Identifying Patients with Intact Neuronal R 0.50 2026-04-25
Temporal Decoupling of CSF p-tau217 Normalization from Amyloid PET Negativity Creates a Du 0.59 2026-04-25
CSF p-tau217 Normalization Requires Intact Synaptic Function and BBB Integrity (Neurodegen 0.52 2026-04-25
Combined p-tau217 + p-tau231 Panel Increases Specificity for Treatment Cessation Determina 0.55 2026-04-25
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clinical Benefits After Treatment C 0.51 2026-04-25
Microglial Reactivation Status Modifies Amyloid Clearance and p-tau217 Normalization Relat 0.52 2026-04-25
CD8+ T-Cell Perforin Pathway as Driver of Neuronal Pyramid Loss 0.71 2026-04-24
C1q-TREM2 Competition for Phosphatidylserine as Pruning Checkpoint 0.68 2026-04-24
TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM 0.72 2026-04-24
SPP1+ DAM as Source of Autoimmunity in Neurodegeneration 0.66 2026-04-24
Astrocyte C3aR Signaling as Bifurcation Point for A1/A2 Fate 0.75 2026-04-24
Mitochondrial Dysfunction in Neurodegeneration 0.46 2026-04-21
Epigenetic Silencing of Tumor Suppressor Genes in Cancer Progression 0.44 2026-04-21
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.05 2026-04-18
[Archived Hypothesis] 0.26 2026-04-17
[Archived Hypothesis] 0.05 2026-04-17

Showing 25 of 50

Thin Descriptions — 50 flagged WARNING

Hypotheses with description under 100 characters

Item Score/Detail Date
Senescence-Associated Epigenetic Phenotype (SEP) 0.62 2026-04-26
REST Complex Dysregulation as Master Epigenetic Switch 0.57 2026-04-26
H3K9me3 Heterochromatin Loss at Pericentromeric Repeats 0.56 2026-04-26
BET Bromodomain Inhibition for Neuroinflammation Suppression 0.55 2026-04-26
Circulating hs-CRP as Disease-Modifying Target via Microglial IL-1β Amplification 0.54 2026-04-26
PLIN2 (Perilipin-2) Degradation via Autophagy Activation to Clear Disease-Associated Lipid 0.54 2026-04-26
TFEB Activation to Restore Lysosomal Biogenesis in Aged Synapses 0.53 2026-04-26
Polycomb-to-Trithorax Switch at Synaptic Plasticity Genes 0.53 2026-04-26
NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Cat 0.52 2026-04-26
Astrocyte-Specific DGAT1 Inhibition to Prevent Lipid Droplet-Induced Neuroinflammation 0.52 2026-04-26
Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation 0.51 2026-04-26
VPS35 Retromer Restoration to Rescue Endosomal Protein Trafficking 0.51 2026-04-26
Anti-CD47/SIRPα Checkpoint Therapy to Enhance Phagocytic Clearance 0.50 2026-04-26
CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege 0.49 2026-04-26
USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates 0.48 2026-04-26
DNA Methylation Clock Drift at Glial Promoters 0.48 2026-04-26
SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation 0.48 2026-04-26
CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation 0.47 2026-04-26
CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation 0.47 2026-04-26
Hsp70 cochaperone BAG3-mediated Autophagy Activation for Synaptic Protein Quality Control 0.47 2026-04-26
GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization Seeds 0.47 2026-04-26
P2X7 Receptor Antagonism to Block ATP-Induced Microglial Pyroptosis 0.46 2026-04-26
Cathepsin D Replacement to Overcome Lysosomal Protease Deficiency 0.46 2026-04-26
Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation 0.45 2026-04-26
HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis 0.45 2026-04-26

Showing 25 of 50

No Target Gene — 50 flagged WARNING

Hypotheses without an assigned target gene

Item Score/Detail Date
Complement Cascade Inhibition Synaptic Protection 0.87 2026-04-17
Microglial Senescence Prevention via TREM2/SASP Axis 0.85 2026-04-17
Gamma Oscillation Enhancement Synergy 0.84 2026-04-17
Dual-Receptor Antibody Shuttling 0.80 2026-04-13
Lysosomal Cathepsin-Dependent Tau Clearance 0.77 2026-04-17
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy 0.76 2026-04-17
Test: TREM2 enhances amyloid clearance 0.76 2026-04-17
Test: TREM2 enhances amyloid clearance 0.71 2026-04-17
Test: TREM2 enhances amyloid clearance 0.70 2026-04-04
LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Suppression 0.67 2026-04-16
Test: TREM2 enhances amyloid clearance 0.66 2026-04-17
EPO Set Point Calibration Hypothesis 0.65 2026-04-14
Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy 0.64 2026-04-15
Test: TREM2 enhances amyloid clearance 0.64 2026-04-17
TREM2 Super-Agonist Induction of DAM Program 0.63 2026-04-21
Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Para 0.61 2026-04-17
Test: TREM2 enhances amyloid clearance 0.61 2026-04-17
NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for Reverse Se 0.60 2026-04-17
Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targ 0.58 2026-04-17
Oxygen Pressure-Dependent BDNF Cascade: DHHC2/PSD95 Stabilization for Synaptic Rescue 0.58 2026-04-17
Hepcidin-Iron Set Point Hypothesis 0.58 2026-04-14
AMPK Activation to Restore Autophagy and Clear α-Synuclein Aggregates 0.56 2026-04-18
Test: TREM2 enhances amyloid clearance 0.56 2026-04-17
Ferroptosis as Disease-Modifying Amplifier 0.54 2026-04-18
Test: TREM2 enhances amyloid clearance 0.54 2026-04-17

Showing 25 of 50

Duplicate / Near-Duplicate Hypotheses — 50 flagged CRITICAL

Pairs of hypotheses with >=60% title overlap; merge, consolidate, or down-rank the weaker duplicate

Item Score/Detail Date
TREM2-Mediated Astrocyte-Microglia Cross-T vs TREM2-Mediated Astrocyte-Microglia Crossta 100% / shared gene candidate
TREM2-Mediated Astrocyte-Microglia Cross-T vs TREM2-Mediated Astrocyte-Microglia Cross-T 100% / shared gene candidate
TREM2-Mediated Astrocyte-Microglia Cross-T vs TREM2-Mediated Astrocyte-Microglia Cross-T 100% / shared gene candidate
TREM2-Mediated Astrocyte-Microglia Crossta vs TREM2-Mediated Astrocyte-Microglia Cross-T 100% / shared gene candidate
TREM2-Mediated Astrocyte-Microglia Crossta vs TREM2-Mediated Astrocyte-Microglia Cross-T 100% / shared gene candidate
TREM2-Mediated Astrocyte-Microglia Cross-T vs TREM2-Mediated Astrocyte-Microglia Cross-T 100% / shared gene candidate
Extracellular Vesicle Biogenesis Modulatio vs Extracellular Vesicle Biogenesis Modulatio 100% / shared gene candidate
LRP1-Dependent Tau Uptake Disruption vs LRP1-Dependent Tau Uptake Disruption 100% / shared gene candidate
VCP-Mediated Autophagy Enhancement vs VCP-Mediated Autophagy Enhancement 100% / shared gene candidate
TREM2-mediated microglial tau clearance en vs TREM2-mediated microglial tau clearance en 100% / shared gene candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate
Test: TREM2 enhances amyloid clearance vs Test: TREM2 enhances amyloid clearance 100% / title overlap candidate

Showing 25 of 50

High-Value Hypotheses With Weak Debate Support — 49 flagged CRITICAL

Scientifically promising hypotheses whose analyses still have no strong debate record

Item Score/Detail Date
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse 0.00 / 0 debates never
Complement Cascade Inhibition Synaptic Protection 0.00 / 0 debates never
Microglial Senescence Prevention via TREM2/SASP Axis 0.00 / 0 debates never
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome 0.00 / 0 debates never
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the 0.00 / 0 debates never
Gamma Oscillation Enhancement Synergy 0.00 / 0 debates never
SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via PGC1alpha 0.00 / 0 debates never
SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent Neuronal an 0.00 / 0 debates never
Dual-Receptor Antibody Shuttling 0.00 / 0 debates never
Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents Both Cyto 0.00 / 0 debates never
Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector 0.00 / 0 debates never
APOE4-Specific Proteolytic Fragment Inhibition Therapy 0.00 / 0 debates never
Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway 0.00 / 0 debates never
Lysosomal Cathepsin-Dependent Tau Clearance 0.00 / 0 debates never
Hypothesis 3: HepaCAM-Containing Extracellular Vesicles 0.00 / 0 debates never
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy 0.00 / 0 debates never
Test: TREM2 enhances amyloid clearance 0.00 / 0 debates never
Astrocyte C3aR Signaling as Bifurcation Point for A1/A2 Fate 0.00 / 0 debates never
TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM 0.00 / 0 debates never
Test: TREM2 enhances amyloid clearance 0.00 / 0 debates never
CD8+ T-Cell Perforin Pathway as Driver of Neuronal Pyramid Loss 0.00 / 0 debates never
Test: TREM2 enhances amyloid clearance 0.00 / 0 debates never
Endothelial NRF2 Activation as a Master Switch for Post-CA BBB Protection 0.00 / 0 debates never
C1q-TREM2 Competition for Phosphatidylserine as Pruning Checkpoint 0.00 / 0 debates never
SPP1+ DAM as Source of Autoimmunity in Neurodegeneration 0.00 / 0 debates never

Showing 25 of 49

Stale Market Pricing — 14 flagged WARNING

Hypotheses whose latest debate evidence is newer than their latest price update

Item Score/Detail Date
Hippocampus ages transcriptionally faster than cerebellum, defining a regional vulnerabili 1 price events 2026-04-24 / 2026-04-23
APOE and TREM2 interact to modulate age-dependent microglial dysfunction 1 price events 2026-04-24 / 2026-04-23
Age-driven synaptic gene silencing precedes neuronal loss in vulnerable brain regions 1 price events 2026-04-24 / 2026-04-23
Hippocampal mitochondrial dysfunction accelerates with age and drives regional AD vulnerab 1 price events 2026-04-24 / 2026-04-23
Age-related neuroinflammation mimics early Alzheimer's disease pathology 1 price events 2026-04-24 / 2026-04-23
Autophagy-Senescence Axis Therapeutic Window 104 price events 2026-04-23 / 2026-04-22
Oligodendrocyte Precursor Cell Senescence in White Matter Disease 78 price events 2026-04-23 / 2026-04-22
Wnt/β-catenin Pathway Restoration 69 price events 2026-04-23 / 2026-04-22
Time-Dependent BBB Repair Strategy 62 price events 2026-04-23 / 2026-04-22
Apoptosis-Senescence Decision Point Intervention 58 price events 2026-04-23 / 2026-04-22
APOE4-Driven Astrocyte Senescence as Primary Target 65 price events 2026-04-23 / 2026-04-22
Peripheral-to-Central Inflammation Circuit Breaker 50 price events 2026-04-23 / 2026-04-22
Cross-Tissue Communication Disruption 76 price events 2026-04-23 / 2026-04-22
Selective Microglial Senescence Targeting via TREM2 Modulation 91 price events 2026-04-23 / 2026-04-22

Artifact Quality Gates — All Types

1811 artifact(s) evaluated · JSON summary →

Type Gate Pass Fail Pass Rate
dataset metadata 10 0
100%
dataset provenance 10 0
100%
dataset schema 0 10
0%
dataset size 10 0
100%
dataset title 10 0
100%
experiment_proposal metadata 7 0
100%
experiment_proposal title 7 0
100%
funding_proposal metadata 7 0
100%
funding_proposal title 7 0
100%
model data_provenance 0 1
0%
model metadata 1 0
100%
model specification 0 1
0%
model title 1 0
100%
model validation 1 0
100%
open_question metadata 1731 0
100%
open_question title 1731 0
100%
paper_figure metadata 55 0
100%
paper_figure title 55 0
100%

Quality Trend History

Time Total No Evid. Low Score Weak Deb. No KG Low Val. Failed No Synth. Orphaned
2026-04-16 11:04 526 51 0 24 51 14 200 1 62
2026-04-16 12:05 757 51 0 27 51 14 200 1 62
2026-04-16 13:13 544 53 0 31 52 14 201 1 64
2026-04-16 14:24 551 54 0 31 52 14 202 1 66
2026-04-16 15:33 559 56 0 31 52 14 202 1 68
2026-04-16 16:38 567 58 0 31 52 14 202 1 70
2026-04-16 17:44 1385 61 0 32 52 14 202 1 73
2026-04-16 19:47 643 77 0 45 52 14 202 1 82
2026-04-16 20:54 647 86 1 18 52 14 202 1 89
2026-04-16 22:24 676 91 1 26 53 14 202 1 94
2026-04-16 23:24 773 95 1 26 54 94 202 1 98
2026-04-17 00:30 778 103 1 26 52 94 202 1 99
2026-04-17 01:49 764 95 1 26 48 94 202 1 99
2026-04-17 03:09 760 96 1 15 48 94 203 1 102
2026-04-17 04:17 1524 96 1 15 51 94 199 1 102
2026-04-17 05:30 747 96 1 14 39 94 200 1 102
2026-04-17 10:42 1622 91 1 32 53 94 202 1 103
2026-04-17 15:11 614 101 0 20 54 96 1 1 111
2026-04-17 16:17 630 105 0 20 54 96 1 1 115
2026-04-17 17:24 634 106 0 20 54 96 1 1 116
2026-04-17 18:28 629 101 0 20 54 96 1 1 116
2026-04-17 20:09 642 104 0 20 54 96 2 1 119
2026-04-17 21:12 1471 105 0 20 54 96 2 1 120
2026-04-18 02:45 1593 105 0 20 54 96 2 1 120
Quality Gates JSON API → ← Back to Senate
Dashboard | Senate